Ya disponibles las comunicaciones GETECCU que serán presentadas en ECCO 2025 divididas por tipo de comunicación:

DOP

  • DOP038 Impact of prenatal and breastfeeding exposure to biologic drugs on the first-year anthropometric development of infants born to mothers with inflammatory bowel disease from DUMBO registry of GETECCU

Póster

  • P0226 Postoperative recurrence after a definitive ostomy in Crohn’s disease. A nationwide retrospective series from the Eneida registry
  • P0254 Cost of telemonitoring with the App TECCU in Inflammatory Bowel Disease compared to standard care in Spain: a multicenter clinical trial of GETECCU
  • P0435 Comparative analysis between capsule endoscopy and ileocolonoscopy for activity detection in ileal Crohn’s disease. Preliminary results from the CAPITER study, a multicenter study from the Young Group of GETECCU
  • P0609 Real-world short and long-term effectiveness of risankizumab in refractory Crohn’s disease: RISANCROHN study from the ENEIDA Registry
  • P0620 Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn’s Disease. Data from the ENEIDA registry
  • P0664 Effectiveness and safety of upadacitinib in ulcerative colitis in clinical practice: results from the U-REAL-UC study from ENEIDA
  • P0692 Comparing JAK inhibitors in ulcerative colitis: which one truly leads in the real world? Results from the ENEIDA registry of GETECCU
  • P0741 Adherence to mesalazine suppositories maintenance treatment in patients with ulcerative proctitis: MESUPO multicenter prospective observational study from GETECCU
  • ​​P0849 Real-world efficacy and safety of filgotinib in ulcerative colitis: results from the ENEIDA registry
  • P0888 Time-trends in the management of postoperative Crohn’s Disease and its impact on long-term surgical recurrence. Data from the ENEIDA registry
  • P0890 Real-World Outcomes of Upadacitinib in Crohn’s Disease: Insights from ENEIDA database
  • P1016 Leishmaniasis in patients with inflammatory bowel disease: a national multicenter study of GETECCU
  • P1227 Predictors of biologics/JAKi use, surgeries, and hospitalisations in a newly diagnosed cohort of IBD patients: Long-term outcomes from the nationwide EpidemIBD study of GETECCU